Drug Trial Radar · NCT06889012
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 7, 2025
Primary completion
Jul 23, 2025
Study completion Jul 23, 2025
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the pharmacokinetics and the safety after administration of BR1018 and coadministration of BR1018A and BR1018B in healthy volunteers
Conditions
- Essential Hypertension
- Primary Hypercholesterolemia
Interventions
BR1018Drug
One tablet administered alone
BR1018ADrug
One tablet administered alone
BR1018BDrug
One tablet administered alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCtTime frame: 0-72 hours after administration
- CmaxTime frame: 0-72 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Center, H PLUS Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.